|Dr. Paul A. Wagner Ph.D.||CEO & Chairman||752.5k||N/A||1970|
|Mr. Antony A. Riley CPA||Chief Financial Officer||456k||N/A||1967|
|Dr. Hubert C. Chen M.D.||Pres & Chief Scientific Officer||N/A||N/A||1969|
|Mr. Christopher Roenfeldt||Chief Operating Officer||N/A||N/A||N/A|
|Mr. Steven Ruhl||Chief Technical Officer||N/A||N/A||1957|
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
Forte Biosciences, Inc.’s ISS Governance QualityScore as of July 31, 2022 is 8. The pillar scores are Audit: 9; Board: 8; Shareholder Rights: 8; Compensation: 7.